

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/atm-21-6731	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The survival data will be shared.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	No.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, because the survival date may be updated over time.
7	To whom will you share the data?	Medical oncologists who are interested in studies of colorectal liver metastases.
8	For what type of analysis or purpose?	For analysis to evaluate the efficacy of triplet chemotherapy plus bevacizumab in RAS/BRAF/PIK3CA mutant colorectal liver-limited metastases.
9	How or where can the data/documents be obtained?	Emails can be sent to the corresponding author.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.